Abstract:Background: This study aims to explore the variations of hepatic vascular geometries in patients with clinically significant portal hypertension (CSPH) and investigate the capability of using CT/MRI angiographic imaging-based vascular geometrical model (VGM) to identify CSPH patients. Methods: A total of 64 vascular geometrical parameters were extracted from the portal vein (PV), hepatic vein (HV), aorta and inferior vena cava and then fed into a VGM for identification of CSPH patients. A total of 853 consecutive liver cirrhosis patients from 3 medical centers who underwent contrast-enhanced imaging within 14 days of transjugular catheterization for hepatic venous pressure gradient (HVPG) were included. The VGM model was trained and validated on a CT cohort containing 256 cirrhosis patients and 202 age-matched participants without a history of chronic liver diseases, and tested on both CT and MR cohorts. Findings: Significant reduction of whole vessel volumes were observed in both PV (from 36·90±15·99 to 29·61±11·07 cm3) and HV (from 35·28±21·47 to 22·44±15·65 cm3) when CSPH occurred. Similarly, whole vessel lengths were reduced in CSPH patients in both PV (from 3·00±2·37 to 1·72±1·23 m) and HV (from 1·83±1·48 to 0·91±1·51 m). The number of external associations of vessel parameters (defined as R>0·5) increased when CSPH occurred, which verified the derangement of the vascular system in the liver. The performance of VGM outperformed conventional clinical models significantly in both internal and external validation cohorts. Interpretation: This study developed and validated a contrast-enhanced CT/MRI-based VGM with good diagnostic consistency to the HVPG measurement, which shows good potential for clinical applications.Trial Registration: We conducted this study using the database of a CT cohort (CHESS1701; ClinicalTrials.gov identifier: NCT03138915) between August 2016 and September 2017 and a MR cohort (CHESS1802; ClinicalTrials.gov identifier: NCT03766880) from December 2018 toApril 2019.Funding: This study was funded by the National Natural Science Foundation of China (No. 81971583, No. 62001120), National Key R&D Program of China (No. 2018YFC1312900, No. 2019YFA0709502), Science Fund for Distinguished Young Scholars (No. 20JR10RA713), Shanghai Natural Science Foundation (No. 20ZR1406400), Shanghai Municipal Science and Technology Major Project (No.2017SHZDZX01, No.2018SHZDZX01), Shanghai Municipal Science and Technology (No.17411953600), Shanghai Sailing Program (No. 20YF1402400), ZJLab and Key Laboratory of Computational Neuroscience and BrainInspired Intelligence (Fudan University), Ministry of Education, China.Declaration of Interest: The authors declare no conflict of interest.Ethical Approval: The study was in agreement with the ethical guidelines of the 1975 Declaration ofHelsinki and approved by the Ethics Committee of the Fifth Medical Center at PLAGeneral Hospital. The requirement for informed consent was waived.

Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Carvedilol to prevent decompensation of liver cirrhosis in patients with clinically significant portal hypertension stratified by novel non-invasive model

Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China

Carvedilol and Its New Analogs Suppress Arrhythmogenic Store Overload–induced Ca2+ Release

Prognostic Value of Virtual Portal Pressure Gradient Response in Compensated Cirrhotic Patients Treated with Carvedilol.

Tolerance of Carvedilol Treatment in Elderly Patients with Chronic Heart Failure

Effects of Carvedilol on Circulating Levels of Endothelin and Von Willebrand Factor in Patients with Unstable Angina Pectoris

Carvedilol Plus NUC for Patients with HBV-Compensated Cirrhosis under Virological Suppression: A Randomized Open-Label Trial.

The Association Between Hepatic Venous Pressure Gradient Baseline and the Response Rate of Carvedilol on Portal Hypertension

Advances in carvedilol to cirrhotic portal hypertension

A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): an International Multicenter Cohort Study.

Lowering hepatic venous pressure agent carvedilol versus variceal banding ligation for clinical outcomes of cirrhotic portal hypertension

Baveno-VII Criteria to Predict Decompensation and Initiate Non-Selective Beta-Blocker in Compensated Advanced Chronic Liver Disease Patients

The influence of carvedilol posology timing on clinically significant portal hypertension: insights from elastography measurements

A Novel Model for the Screening of Varices in Patients with Compensated Cirrhosis: an International Multicenter Study

CLIF-C AD score predicts survival benefit from pre-emptive TIPS in individuals with Child-Pugh B cirrhosis and acute variceal bleeding

The Efficacy of Carvedilol in Comparison to Propranolol in Reducing the Hepatic Venous Pressure Gradient and Decreasing the Risk of Variceal Bleeding in Adult Cirrhotic Patients: A Systematic Review

The effect of sustained-release CARvedilol in patients with hypErtension and heart failure with preserved ejection fraction: a study protocol for a pilot randomized controlled trial (CARE-preserved HF)

Carvedilol suppresses circulating and hepatic IL-6 responsible for hepatocarcinogenesis of chronically damaged liver in rats

Development and Validation of a Hepatic Vascular Geometrical Model for Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802)